Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-q6k6v Total loading time: 0 Render date: 2024-07-08T14:24:39.151Z Has data issue: false hasContentIssue false

Chapter 19 - Management of non-Hodgkin's lymphoma in older adults

from Part 3 - Management of hematologic malignancies in older adults

Published online by Cambridge University Press:  05 August 2011

By
Anne H. Blaes  and
Vicki A. Morrison
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 274 - 287
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefGoogle ScholarPubMed
,American Cancer Society. Cancer facts and figures. American Cancer Society Web site. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
Devesa, SS, Fears, T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992;52:5432s–5440s.Google ScholarPubMed
Coleman, MP, Esteve, J, Damiecki, P. Trends in cancer incidence and mortality. IARC Sci Publ. 1993;121:1–806.Google Scholar
Newton, R, Ferlay, J, Beral, V. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997;72:923–930.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Thieblemont, C, Coiffier, B. Lymphoma in older patients. J Clin Oncol. 2007;25:1916–1923.CrossRefGoogle ScholarPubMed
Roche, LM, Paul, SM, Costa, SJ. Acquired immune deficiency syndrome and the increase in non-Hodgkin lymphoma incidence in New Jersey from 1979 to 1996. Cancer. 2001;92:2948–2956.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Roche, LM, Weinstein, RB, Paul, SM. Cancer in people with AIDS in New Jersey. N J Med. 2001;98:27–36.Google ScholarPubMed
Zheng, T, Mayne, ST, Boyle, P. Epidemiology of non-Hodgkin lymphoma in Connecticut: 1935–1988. Cancer. 1992;70:840–849.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Ries, LAG, Melbert, D, Krapcho, M. SEER cancer statistics review, 1975–2006. National Cancer Institute Web site. Available at: http://seer.cancer.gov/csr/1975_2006/index.html.
Kennedy, BJ. Aging and cancer. J Clin Oncol. 1988;6:1903–1911.CrossRefGoogle ScholarPubMed
Satariano, WA, Ragland, DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–110.CrossRefGoogle ScholarPubMed
Yancik, R, Wesley, MN, Ries, . Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc. 2001;285:885–892.CrossRefGoogle ScholarPubMed
Terret, C, Zulian, GB, Naiem, A. Multidisciplinary approach to the geriatric oncology patient. J Clin Oncol. 2007;25:1876–1881.CrossRefGoogle ScholarPubMed
Hershman, DL, McBride, RB, Eisenberger, A. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159–3165.CrossRefGoogle ScholarPubMed
Guralnik, J, LaCroix, A, Everett, D. Ageing in the Eighties: The Prevalence of Comorbidity and Its Association with Disability. Advance Data from Vital Health Statistics. Hyattsville, MD: National Center for Health Statistics; 1989.Google Scholar
Polednak, AP. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer Detect Prev. 2006; 30(5):466–472.CrossRefGoogle ScholarPubMed
Aapro, MS, Kohne, CH, Cohen, HJ. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10:198–204.CrossRefGoogle Scholar
Dixon, , Neilan, B, Jones, SE. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295–305.CrossRefGoogle ScholarPubMed
Vose, JM, Armitage, JO, Weisenburger, DD. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838–1844.CrossRefGoogle ScholarPubMed
Maartense, E, Kluin-Nelemans, HC, Cessie, S. Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Cancer. 2000;89:2667–2676.3.0.CO;2-P>CrossRefGoogle ScholarPubMed
Maartense, E, Kluin-Nelemans, HC, Noordijk, EM. Non-Hodgkin's lymphoma in the elderly: a review with emphasis on elderly patients, geriatric assessment, and future perspectives. Ann Hematol. 2003;82:661–670.CrossRefGoogle ScholarPubMed
Levine, PH, Hoover, R. The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors. Cancer Epidemiol Biomarkers Prev. 1992;1(6):515–517.Google ScholarPubMed
Fisher, SG, Fisher, RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23(38):6524–6534.CrossRefGoogle ScholarPubMed
Harris, NL, Jaffe, ES, Stein, H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392.Google ScholarPubMed
Thieblemont, C, Coiffier, B. Lymphoma in older patients. J Clin Oncol. 2007;25:1916–1923.CrossRefGoogle ScholarPubMed
Greiner, TC, Medeiros, LJ, Jaffe, ES. Non-Hodgkin's lymphoma. Cancer. 1995;75:370–380.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
Ballester, OF, Moscinski, L, Spiers, A. Non-Hodgkin's lymphoma in the older person: a review. J Am Geriatr Soc. 1993;41:1245–1254.CrossRefGoogle ScholarPubMed
Doll, DC, Weiss, RB. Malignant lymphoma of the testis. Am J Med. 1986;81:515–524.CrossRefGoogle ScholarPubMed
Willemze, R, Ruiter, DJ, Vloten, WA. Reticulum cell sarcomas (large cell lymphomas) presenting in the skin: high frequency of true histiocytic lymphoma. Cancer. 1982;50:1367–1379.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Carbone, PP, Kaplan, HS, Musshoff, K. Report of the Committee on Hodgkin's Disease staging classification. Cancer Res. 1971;31:1860–1861.Google Scholar
Miller, TP, Lippman, SM, Spier, CM. HLA-DR (ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest. 1988;82:370–372.CrossRefGoogle ScholarPubMed
Swan, F, Huh, Y, Katz, R. Beta-2 microglobulin (B2M) and HLA-DR cellular expression in relapsing large cell lymphomas (LCL): relationship to survival and serum B2M levels. Blood. 1990;76:375a.Google Scholar
Bauer, KD, Merkel, , Winter, JN. Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res. 1986;46:3173–3178.Google ScholarPubMed
McKelvey, EM, Gottlieb, JA, Wilson, HE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38(4):1484–1493.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Fisher, RI, Gaynor, ER, Dahlberg, S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006.CrossRefGoogle ScholarPubMed
Czuczman, MS, Grillo-López, AJ, White, CA. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276.CrossRefGoogle ScholarPubMed
Czuczman, MS, Grillo-López, AJ, McLaughlin, P. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol. 2001;12:109–114.CrossRefGoogle ScholarPubMed
Czuczman, MS, Weaver, R, Alkuzweny, B. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716.CrossRefGoogle ScholarPubMed
Vose, JM, Link, BK, Grossbard, ML. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389–397.CrossRefGoogle ScholarPubMed
Coiffier, B, Lepage, E, Brière, J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.CrossRefGoogle ScholarPubMed
Coiffier, B, Feugier, P, Mounier, N. Long term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25(suppl):8009.Google Scholar
Habermann, TM, Weller, EA, Morrison, VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.CrossRefGoogle ScholarPubMed
Morrison, VA, Weller, EA, Habermann, TM. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an intergroup E4494/C9793 update. J Clin Oncol. 2007;25(suppl):8011.Google Scholar
Pfreundschuh, M, Trumper, L, Kloess, M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641.CrossRefGoogle ScholarPubMed
Pfreundschuh, M, Schubert, J, Ziepert, M. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.CrossRefGoogle Scholar
Tholstrup, D, Nully Brown, P, Jurlander, J. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2007;79:100–106.CrossRefGoogle ScholarPubMed
O';Connell, MJ, Earle, JD, Harrington, DP. Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol. 1986;4:1418.Google Scholar
Campbell, C, Sawka, C, Franssen, E. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Leuk Lymphoma. 1999;35:119–127.CrossRefGoogle ScholarPubMed
Sonneveld, P, Huijgens, PC, Hagenbeek, A. Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma. Ned Tijdschr Geneeskd. 1999;143:418–419.Google Scholar
Jacobson, JO, Grossbard, M, Shulman, LN. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Clin Lymphoma. 2000;1:211–217; discussion 218.CrossRefGoogle ScholarPubMed
Liang, R, Todd, D, Chan, TK. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma. Hematol Oncol. 1993;11:43–50.CrossRefGoogle ScholarPubMed
Sonneveld, P, Ridder, M, Lelie, H. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530–2539.CrossRefGoogle ScholarPubMed
Sonneveld, P, Michiels, JJ. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer. 1990;62:105–108.CrossRefGoogle ScholarPubMed
Bessell, EM, Coutts, A, Fletcher, J. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology. Eur J Cancer. 1994;30A:1337–1341.CrossRefGoogle ScholarPubMed
Salvagno, L, Contu, A, Bianco, A. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol. 1992;3:833–837.CrossRefGoogle ScholarPubMed
Ansell, SM, Falkson, G. A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol. 1993;4:172.CrossRefGoogle ScholarPubMed
Tirelli, U, Zagonel, V, Errante, D. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol. 1992;10:228–236.CrossRefGoogle ScholarPubMed
Zagonel, V, Tirelli, U, Carbone, A. Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. Cancer Invest. 1990;8:577–582.CrossRefGoogle ScholarPubMed
Bertini, M. Therapeutic strategies in intermediate grade lymphomas in elderly patients. the Italian Multiregional Non Hodgkin's Lymphoma Study Group (IMRNHLSG). Hematol Oncol. 1993;11(suppl 1):52–58.Google Scholar
Morra, E, Gargantini, L, Nosari, A. Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators. Crit Rev Oncol Hematol. 2000;35:95–100.CrossRefGoogle ScholarPubMed
Zaja, F, Tomadini, V, Zaccaria, A. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47:2174–2180.CrossRefGoogle ScholarPubMed
Martino, R, Perea, G, Caballero, MD. Cyclophosphamide, pegylated liposomal doxorubicin (caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica. 2002;87:822–827.Google ScholarPubMed
Italiano, A, Jardin, F, Peyrade, F. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica. 2005;90:1281–1283.Google ScholarPubMed
Chao, NJ, Rosenberg, SA, Horning, SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood. 1990;76(7): 1293–1298.Google ScholarPubMed
Cardinale, D, Colombo, A, Sandri, MT. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114:2474–2481.CrossRefGoogle ScholarPubMed
Kalay, N, Basar, E, Ozdogru, I. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–2262.CrossRefGoogle ScholarPubMed
Doorduijn, JK, Holt, B, Imhoff, GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041–3050.CrossRefGoogle ScholarPubMed
Osby, E, Hagberg, H, Kvaloy, S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood. 2003;101:3840–3848.CrossRefGoogle ScholarPubMed
Gómez, H, Mas, L, Casanova, L. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352–2358.CrossRefGoogle ScholarPubMed
Gómez, H, Hidalgo, M, Casanova, L. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065–2069.CrossRefGoogle ScholarPubMed
Morrison, VA, Weller, EA, Habermann, TM. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). Proc Am Soc Hematol. 2004;104:904a.Google Scholar
Smith, TJ, Khatcheressian, J, Lyman, GH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol. 2006;24:3187–3285.CrossRefGoogle Scholar
Advani, R, Rosenberg, SA, Horning, SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–1459.CrossRefGoogle Scholar
Horning, SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:75–88.Google ScholarPubMed
Horning, SJ, Rosenberg, SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311: 1471–1475.CrossRefGoogle ScholarPubMed
O';Reilly, SE, Connors, JM, Macpherson, N. Malignant lymphomas in the elderly. Clin Geriatr Med. 1997;13:251–263.Google Scholar
Engelhard, M, Stuschke, M. 3. Report on workshop: UICC workshop “therapy of NHL in early stages,” part 1: follicular lymphoma. Ann Hematol. 2001;80(suppl 3):B13–B15.Google ScholarPubMed
Mac Manus, MP, Hoppe, RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282–1290.CrossRefGoogle Scholar
Gospodarowicz, MK, Bush, RS, Brown, TC. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10:489–497.CrossRefGoogle ScholarPubMed
Pendlebury, S, el Awadi, M, Ashley, S. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol. 1995;36:167–171.CrossRefGoogle ScholarPubMed
Tezcan, H, Vose, JM, Bast, M. Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Leuk Lymphoma. 1999;34:273–285.CrossRefGoogle Scholar
Ardeshna, KM, Smith, P, Norton, A. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522.CrossRefGoogle ScholarPubMed
Kelsey, SM, Newland, AC, Hudson, GV. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19–25.CrossRefGoogle ScholarPubMed
Connors, JM, O';Reilly, SE. Treatment considerations in the elderly patient with lymphoma. Hematol Oncol Clin North Am. 1997;11:949–961.CrossRefGoogle ScholarPubMed
Jones, SE, Rosenberg, SA, Kaplan, HS. Non-Hodgkin's lymphomas. II. Single agent chemotherapy. Cancer. 1972;30:31–38.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Kennedy, BJ, Bloomfield, CD, Kiang, DT. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer. 1978;41:23–28.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Anderson, T, Bender, RA, Fisher, RI. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep. 1977;61:1057–1066.Google ScholarPubMed
Jones, SE, Grozea, PN, Miller, TP. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1985;3:1318–1324.CrossRefGoogle ScholarPubMed
Jones, SE, Grozea, PN, Metz, EN. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979;43:417–425.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Glick, JH, Barnes, JM, Ezdinli, EZ. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood. 1981;58:920–925.Google ScholarPubMed
Peterson, BA, Petroni, GR, Frizzera, G. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21:5–15.CrossRefGoogle ScholarPubMed
McLaughlin, P, Hagemeister, FB, Romaguera, JE. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262–1268.CrossRefGoogle ScholarPubMed
Maloney, DG, Grillo-López, AJ, White, CA. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–2195.Google ScholarPubMed
McLaughlin, P, Grillo-López, AJ, Link, BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833.CrossRefGoogle ScholarPubMed
Feuring-Buske, M, Kneba, M, Unterhalt, M. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group. Ann Hematol. 2000;79:493–500.CrossRefGoogle ScholarPubMed
Hainsworth, JD, Litchy, S, Burris III, HA. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261–4267.CrossRefGoogle ScholarPubMed
Witzig, TE, Vukov, AM, Habermann, TM. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103–1108.CrossRefGoogle ScholarPubMed
Colombat, P, Salles, G, Brousse, N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–106.CrossRefGoogle ScholarPubMed
Schulz, H, Bohlius, JF, Trelle, S. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–714.CrossRefGoogle ScholarPubMed
Hiddemann, W, Kneba, M, Dreyling, M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.CrossRefGoogle ScholarPubMed
Witzig, TE, Flinn, IW, Gordon, LI. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262–3269.CrossRefGoogle ScholarPubMed
Witzig, TE, Gordon, LI, Cabanillas, F. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453–2463.CrossRefGoogle ScholarPubMed
Kaminski, MS, Tuck, M, Estes, J. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449.CrossRefGoogle ScholarPubMed
Leonard, JP, Coleman, M, Kostakoglu, L. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696–5704.CrossRefGoogle ScholarPubMed
Zallio, F, Cuttica, A, Caracciolo, D. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma. Ann Hematol. 2002;81:448–453.CrossRefGoogle ScholarPubMed
Jantunen, E, Mahlamaki, E, Nousiainen, T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant. 2000;26:737–741.CrossRefGoogle ScholarPubMed
Jantunen, E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant. 2006;38:715–720.CrossRefGoogle ScholarPubMed
Jantunen, E, Itala, M, Juvonen, E. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant. 2006;37:367–372.CrossRefGoogle ScholarPubMed
Jantunen, E, Canals, C, Rambaldi, A. Autologous stem cell transplantation in elderly patients (>= 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation Registry. Haematologica. 2008;93:1837–1842.CrossRefGoogle ScholarPubMed
Wallen, H, Gooley, TA, Deeg, HJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23:3439–3446.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×